DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well dynamic contrast enhanced molecular resonance
imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in
assessing tumor response to chemotherapy in patients with triple negative breast cancer
(TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI
may help researchers predict which patients may respond to treatment.